1.Study on the role of microRNA-195 in transforming growth factor-β/Smad signal pathway and the fibrosis mechanism
Yu-Tao MA ; Yang HE ; Pei-Pei MENG ; Shan-Ru ZUO ; Ren GUO ; Shi-Kun LIU
The Chinese Journal of Clinical Pharmacology 2017;33(20):2035-2038
Objective To explore the effect of miRNA-195 (miR-195) on Smad7 expression and rat hepatic stellate cells line (HSC-T6) activation incuced by transforming growth factor-β1 (TGF-β1).Methods HSC-T6 were cultured in vitro,with 5 ng · mL-1 TGF-β1 as an injury factor simulating the rats liver fibrosis models.The cells divided into six groups:control group,model group (TGF-β1 group),miR-195 mimic experimental group,miR-195.mimic NC experimental group,miR-195 inhibitor experimental group and miR-195 inhibitor NC experimental group.After the HSC-T6 treated with 5 ng · mL-1 TGF-β1for 24,48,72 h,the mRNA expression of miR-195,Smad7,and α-SMA was detected by Real-time PCR.The protein expression of Smad7 was detected by Western blot.Results Under the induced by TGF-β1,the expression of miR-195 increased gradually (P < 0.01),the expression of Smad7 showed a decreasing trend (P < 0.05),and the expression of oα-SMA was gradually upregulated (P < 0.01) with time.Compared with the model group,miR-195 mimic could promote activation of HSC-T6 induced by TGF-β1,and increase miR-195,α-SMA mRNA expression (all P <0.01),as well as reduce Smad7 mRNA and protein expression (all P <0.01);while miR-195 inhibitor could inhibit activation of HSC-T6 induced by TGF-β1,decrease miR-195,α-SMA mRNA expression (all P < 0.01),as well as upregulate Smad7 mRNA and protein expression (all P < 0.01).Conclusion miR-195 is involved in pro-activation of HSC-T6 by inhibiting Smad7 expression.
2.Clinical investigation of 144 patients with drug-induced liver injury and its influencing factors analysis
Pei-Pei MENG ; Shi-Kun LIU ; Yang HE ; Yu-Tao MA ; Shan-Ru ZUO ; Li-Ying SONG ; Chun-Jiang WANG
The Chinese Journal of Clinical Pharmacology 2017;33(5):467-469,473
Objective In order to provide support for the rational use of drugs,we summarize the clinical characteristics of patients with drug-induced liver injury (DILI) and statistics of the allergic drugs.Methods According to the common drug-induced liver injury diagnostic criteria of our country,the clinical data of 144 hospitalized cases in the third Xiangya hospital with DILI were analyzed retrospectively,then,potential pathogenic drugs were summarized.Results A total of 144 patients with DILI were enrolled in this study:male account for 53.47% (77/144 cases),female account for 46.53% (67/144 cases).The average age was (44.32 ± 16.02) years old,and 50.70% (73/144 cases) of the patients were over 40 years old.Liver injury was caused by several kinds of drugs,23.61% (34/144 cases) were traditional Chinese medicine,20.83% (30/144 cases)were immunosuppressive agents,15.97% (23/144 cases) were anti-tuberculosis drugs,7.64% (11/144 cases) were antineoplastic drugs.18.75% (27/144 cases) patients were cured,22.92% (33/144 cases) patients got better while others account for 58.33% (84/144 cases),and the average hospitalization days of patients with DILI were 16 days.Age,gender and duration of the disease had no significant effect on prognosis (P > 0.05),while there were significant differences between liver function indexes and prognosis (P <0.05).Conclusion In this study,the incidence of DILI was higher in elderly people.A variety of drugs were able to cause DILI,including traditional Chinese medicine,immunosuppressive agents and anti-tuberculosis drugs.